Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma in situ and referred for genetic testing

Cancer Prevention Research

Volumn 3, Issue 12, 2010, Pages 1579-1585

  Hall, Michael J ^a   Reid, Julia E ^b   Wenstrup, Richard J ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b Utah   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CANCER RISK; CARCINOMA IN SITU; DNA SEQUENCE; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC RISK; GENETIC SCREENING; HUMAN; INTRADUCTAL CARCINOMA; JEW; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; ONSET AGE; OVARY CANCER; PREVALENCE; PRIORITY JOURNAL;

AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; FEMALE; GENETIC TESTING; HUMANS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PREVALENCE; RISK FACTORS;

EID: 78650372104     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0218     Document Type: Article

References (35)

1. Li CI, Daling JR, Malone KE. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980-2001. Cancer Epidemiol Biomarkers Prev 2005;14(4):1008-11.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-49.
3. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66-71. (Pubitemid 24345325)
4. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789-792.
5. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343(8899):692-5.
6. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. New Engl J Med 1997;336(20):1401-8.
7. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004;22(12):2328-35.
8. Verhoog LC, Brekelmans CTM, Seynaeve C, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998;351 (9099):316-21.
9. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 1997;60(3):496-504. (Pubitemid 27097597)
10. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol 2004;22(6):1055-62.
11. Kauff ND, Domchek SM, Friebel T, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 2008;26(8):1331-7.
12. Narod SA, Offit K. Prevention and management of hereditary breast cancer. J Clin Oncol 2005;13:1656-63. (Pubitemid 46211420)
13. Sun CC, Lenoir G, Lynch H, Narod SA. In-situ breast cancer and BRCA1. Lancet 1996;348(9024):408.
14. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Nat Cancer Inst 1998;90(15):1138-45.
15. Breast Cancer Linkage Consortium: pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997;349(9064):1505-10.
16. Claus EB, Petruzzela S, Matloff E, Carter D. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA 2005;293(8):964-9. (Pubitemid 40271128)
17. Hwang ES, McLennan JL, Moore DH, Crawford BB, Esserman LJ, Ziegler JL. Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol 2007;25(6):642-7.
18. Smith KL, Adank M, Kauff N, et al. BRCA mutations in women with ductal carcinoma in situ. Clin Cancer Res 2007;13(14):4306-10.
19. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002;20(6):1480-90.
20. Hall MJ, Ried JE, Burbidge LA, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer 2009;115(10):2222-33.
21. Bansal A, Critchfield GC, Frank TS, et al. The predictive value of BRCA1 and BRCA2 mutation testing. Genet Test 2000;4(1):45-8. (Pubitemid 30217740)
22. http://www.myriadtests.com/provider/doc/BRCA-Mutation-Prevalence- Percentages.pdf[accessed on October 13, 2009].
23. Hendrickson BC, Judkins T, Ward BE, et al. Prevalence of five previously reported and recurrent BRCA1 genetic rearrangement mutations in 20,000 patients from hereditary breast/ovarian cancer families. Genes Chromosomes Cancer 2005;43(3):309-13.
24. Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006;295(12):1379-88.
25. Claus EB, Stowe M, Carter D. Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. Breast Cancer Res Treat 2003;78:7-15. (Pubitemid 36223012)
26. Arun B, Vogel KJ, Lopez A, et al. High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers. Cancer Prev Res 2009;2:122-7.
27. Garber JE. BRCA1/2-associated and sporadic breast cancers: fellow travelers or not? Cancer Prev Res 2009;2:100-3.
28. Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005;365(9473):1769-78.
29. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004;292(11):1317-25.
30. http://www.nccn.org/professionals/physician-gls/PDF/genetics-screening. pdf[accessed on April 12, 2010].
31. http://www.nccn.org/professionals/physician-gls/PDF/breast-risk. pdf[accessed on April 12, 2010].
32. Allred DC, Bryant J, Land S, et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of intraductal breast cancer: findings of the NSABP Protocol B-24 [abstract]. Breast Cancer Res Treat 2002;77(Suppl 1):S36.
33. Goodwin A, Parker S, Ghersi D, Wilcken N. Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database Syst Rev 2009;3:CD000563.
34. van Gestel YR, Voogd AC, Vingerhoets AJ, et al. A comparison of quality of life, disease impact and risk perception in women with invasive breast cancer and ductal carcinoma in situ. Eur J Cancer 2007;43(3):549-56.
35. Fisher ER, Land SR, Fisher B, Mamounas E, Gilarski L, Wolmark N. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ. Cancer 2004;100(2):238-44. (Pubitemid 38063630)